No Data
No Data
William Blair Maintains Solid Biosciences(SLDB.US) With Buy Rating
Solid Biosciences Receives Buy Rating Amid Promising Developments and Accelerated Approval Prospects for SGT-003
Solid Biosciences Added to the Nasdaq Biotechnology Index
SOLiD Awarded NTIA Grant for Open RAN Development Project
PepGen Stock Craters 35% on FDA Clinical Hold
Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst